KPC Pharmaceuticals (SHA:600422) will sell 2.4 million shares it holds in Nanjing Leads Biolabs (HKG:9887) for a total of 132.2 million yuan, according to a Saturday disclosure to the Shanghai bourse.
The divestment of the 1.2283% stake will help KPC focus on its core business and optimize its asset structure.
The selling price will be determined according to the secondary market price of the time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.